UnknownPhase 2NCT03147859

Vedolizumab Treatment in Antiretroviral Drug Treated Chronic HIV Infection

Studying Acquired immunodeficiency

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ottawa Hospital Research Institute
Principal Investigator
Bill Cameron, MD
Ottawa Hospital Research Institute
Intervention
Vedolizumab (brand name Entyvio)(biological)
Enrollment
10 target
Eligibility
18-65 years · All sexes
Timeline
2017 – 2023

Study locations (1)

Collaborators

Cheo Research Institute · Nebraska Centre for Substance Abuse Research

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03147859 on ClinicalTrials.gov

Other trials for Acquired immunodeficiency

Additional recruiting or active studies for the same condition.

See all trials for Acquired immunodeficiency →

← Back to all trials